Anixa Biosciences Inc Stock Price, News & Analysis

Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company whose news flow centers on the treatment and prevention of cancer. Company announcements frequently highlight progress in its ovarian cancer immunotherapy program and its portfolio of cancer vaccines, especially an investigational breast cancer vaccine developed in collaboration with Cleveland Clinic.

News items for ANIX often cover clinical trial milestones, such as completion of a Phase 1 trial, presentation of final data at major scientific meetings, and plans to advance programs into subsequent phases of development. For the breast cancer vaccine targeting α-lactalbumin, disclosures have included safety and immune response findings, details on trial cohorts, and steps to transfer the related IND sponsorship from Cleveland Clinic to Anixa for future trials.

Another recurring theme in Anixa’s news is its ovarian cancer CER-T (CAR-T) program, including regulatory and naming milestones. The company has reported that the World Health Organization’s International Nonproprietary Names Expert Committee approved “liraltagene autoleucel” (lira-cel) as the non-proprietary name for its FSHR-targeted CAR-T therapy, and updates often describe the ongoing first-in-human trial in recurrent ovarian cancer.

Investors and observers can also expect intellectual property updates, such as U.S. and international patent issuances that extend protection for the breast cancer vaccine technology, as well as participation in investor conferences and research-focused fireside chats. Together, these news items provide insight into Anixa’s clinical progress, collaboration activities with institutions like Cleveland Clinic and Moffitt Cancer Center, and the evolution of its immuno-oncology pipeline.